Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.
6 reports, 3 independent
Updated Fri 00:00
Still developing
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Medicus Pharma advances Teverelix protocol to FDA and signs new co-development deal with Pfizer.1 source
Medicus Pharma partners with Pfizer for ADC development funding and advances SkinJect 005 study.1 source
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation